Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state

@article{Tarfi2019DisappearanceOS,
  title={Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state},
  author={Sihem Tarfi and Bouchra Badaoui and Nicolas Freynet and Margot Morabito and Jeffie Lafosse and Andr{\'e}a Toma and Gabriel {\'E}tienne and Jean-Baptiste Micol and Ivan Sloma and Pierre Fenaux and Eric Solary and Doroth{\'e}e S{\'e}limoglu-Buet and Orianne Wagner-Ballon},
  journal={Haematologica},
  year={2019},
  volume={105},
  pages={e147 - e152}
}
The diagnosis of chronic myelomonocytic leukemia (CMML) relies on both a persistent peripheral blood monocytosis (monocytes ≥1x10/L) and monocytes accounting for ≥10% of the white blood cell (WBC) differential count. We showed that a relative accumulation of classical monocytes (cMo: CD14CD16) ≥94% among the total peripheral blood monocytes measured by flow cytometry could help to distinguish CMML from other causes of monocytosis. Since then, the quantification of circulating monocyte subsets… 

Figures and Tables from this paper

Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study

The prognostic value of the distribution of monocyte subset in the peripheral blood of CMML patients has not been explored so far and is not associated with a poor outcome.

ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry.

This ELN multicenter study demonstrates the robustness of the monocyte assay with only limited variability of cMo percentages, validates the 94% cutoff value, confirms its high sensitivity and specificity in PB and also confirms the possibility of its use in BM samples.

Chronic Myelomonocytic Leukemia Gold Jubilee

This review summarizes the progresses made in disease understanding since its recognition and argues for more CMML-dedicated clinical trials.

Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.

The clinicopathologic features of 40 patients with OM-CMML with well-annotated immunophenotypic and molecular data and compared them to those of 56 patients with overt CMML found similar clinical, morphological, and cytogenetic features, support the consideration of OM- CMML as a distinctive subtype of CMML.

6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes

The features of slan+ cells are congruent with the features of CD16+ non-classical monocytes and that slan is a candidate marker for definition of non- classical monocyte.

Chronic myelomonocytic leukemia diagnosis and management

Patients who are low risk but with symptoms from cytopenias or proliferative features such as splenomegaly may be treated with hypomethylating agents (HMAs) or cytoreductive therapy, respectively, with the goal of durable symptoms control.

A hierarchical approach in the diagnostic workflow of chronic myelomonocytic leukemia: Pivotal role of the “Mono‐dysplasia‐score” combined with flow cytometric quantification of monocyte subsets

Three diagnostic approaches are studied: the classical morphology approach, the flow cytometry assay (quantification of monocyte subsets as described by Selimoglu‐Buet et al in 2015), and the “mono‐dysplasia‐score” also referred to as “Monoscore”.

Monocyte subsets to differentiate chronic myelomonocytic leukemia from reactive monocytosis

No specific genetic abnormalities are present in CMML, and reactive monocytosis should be excluded, and an increase in classical monocytes (MO1) has been suggested as a screening tool.

References

SHOWING 1-10 OF 15 REFERENCES

Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia

Quantification of monocyte subsets is useful in clinical practice as a diagnostic marker of CMML in blood and bone marrow specimens and a decreased percentage of nonclassical monocytes showed better sensitivity than the previously described approach.

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.

It is concluded that an increase in the fraction of classical monocytes to >94.0% of total monocytes is a highly sensitive and specific diagnostic marker that rapidly and accurately distinguishes CMML from confounding diagnoses.

Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis

The robustness of the flow assay with limited variability of classical monocyte percentage between centers is demonstrated, validates the 94% cutoff value, and confirms its sensitivity and specificity.

slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation.

Gene expression profiling confirms that slan-negative intermediate monocytes show highest expression levels of major histocompatibility complex class II genes, whereas a differential ubiquitin signature is a novel feature of the slan approach.

The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.

Somatic mutations are detected at high frequency in patients referred with a monocytosis, irrespective of diagnosis, and in those without a World Health Organization-defined diagnosis, the mutation spectrum, immunophenotypic features, and OS are indistinguishable from CMML patients, and these patients should be managed as such.

Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.

To the editor: Even though the diagnosis criteria of chronic myelomonocytic leukemia (CMML) have been recently revised by the World Health Organization (WHO),[1][1] recognition of this disease can

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group

A statstical model is developed that confirms that CGL, aCML and CMML can be distinguished from each other with reasonable success employing five quantitative parameters and one qualitative parameter.

A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset

A mechanistic link between miR-150 and TET3 as being involved in monocyte subset generation is identified, and it is shown that Tet3 knockout mice generate an increased number of non-classical monocytes.

Toward a Refined Definition of Monocyte Subsets

While these cells appear to be in transition from classical to non-classical monocytes and hence may not form a distinct cell population in a strict sense, their separate analysis and enumeration is warranted in health and disease.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Serial sequencing demonstrates that the response to hypomethylating agents is associated with changes in DNA methylation and gene expression, without any decrease in the mutation allele burden, nor prevention of new genetic alteration occurence.